BioCryst Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $6.74
- Today's High:
- $7.095
- Open Price:
- $6.8
- 52W Low:
- $7.2
- 52W High:
- $15.43
- Prev. Close:
- $6.84
- Volume:
- 2774710
Company Statistics
- Market Cap.:
- $1.58 billion
- Book Value:
- -1.738
- Revenue TTM:
- $289.68 million
- Operating Margin TTM:
- -43.8%
- Gross Profit TTM:
- $10.94 million
- Profit Margin:
- -78.1%
- Return on Assets TTM:
- -15.29%
- Return on Equity TTM:
- -1925.37%
Company Profile
BioCryst Pharmaceuticals Inc had its IPO on 1994-03-03 under the ticker symbol BCRX.
The company operates in the Healthcare sector and Biotechnology industry. BioCryst Pharmaceuticals Inc has a staff strength of 531 employees.
Stock update
Shares of BioCryst Pharmaceuticals Inc opened at $6.8 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $6.74 - $7.1, and closed at $6.94.
This is a +1.46% increase from the previous day's closing price.
A total volume of 2,774,710 shares were traded at the close of the day’s session.
In the last one week, shares of BioCryst Pharmaceuticals Inc have slipped by -4.67%.
BioCryst Pharmaceuticals Inc's Key Ratios
BioCryst Pharmaceuticals Inc has a market cap of $1.58 billion, indicating a price to book ratio of 56.5858 and a price to sales ratio of 8.4518.
In the last 12-months BioCryst Pharmaceuticals Inc’s revenue was $289.68 million with a gross profit of $10.94 million and an EBITDA of $-125368000. The EBITDA ratio measures BioCryst Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, BioCryst Pharmaceuticals Inc’s operating margin was -43.8% while its return on assets stood at -15.29% with a return of equity of -1925.37%.
In Q1, BioCryst Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 37.8%.
BioCryst Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- -0.28
Its diluted EPS in the last 12-months stands at $-1.22 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.28. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into BioCryst Pharmaceuticals Inc’s profitability.
BioCryst Pharmaceuticals Inc stock is trading at a EV to sales ratio of 9.4464 and a EV to EBITDA ratio of -23.5071. Its price to sales ratio in the trailing 12-months stood at 8.4518.
BioCryst Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $-669929000.00
- Total Liabilities
- $85.16 million
- Operating Cash Flow
- $-107109000.00
- Capital Expenditure
- $160000
- Dividend Payout Ratio
- 0%
BioCryst Pharmaceuticals Inc ended 2024 with $-669929000.00 in total assets and $0 in total liabilities. Its intangible assets were valued at $-669929000.00 while shareholder equity stood at $-1507953000.00.
BioCryst Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $85.16 million in other current liabilities, 1889000.00 in common stock, $-1507953000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $155.14 million and cash and short-term investments were $401.59 million. The company’s total short-term debt was $0 while long-term debt stood at $232.52 million.
BioCryst Pharmaceuticals Inc’s total current assets stands at $490.88 million while long-term investments were $3.43 million and short-term investments were $243.02 million. Its net receivables were $48.64 million compared to accounts payable of $6.25 million and inventory worth $27.47 million.
In 2024, BioCryst Pharmaceuticals Inc's operating cash flow was $-107109000.00 while its capital expenditure stood at $160000.
Comparatively, BioCryst Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $6.94
- 52-Week High
- $15.43
- 52-Week Low
- $7.2
- Analyst Target Price
- $15.15
BioCryst Pharmaceuticals Inc stock is currently trading at $6.94 per share. It touched a 52-week high of $15.43 and a 52-week low of $15.43. Analysts tracking the stock have a 12-month average target price of $15.15.
Its 50-day moving average was $7.17 and 200-day moving average was $8.75 The short ratio stood at 10.27 indicating a short percent outstanding of 0%.
Around 107.2% of the company’s stock are held by insiders while 8707.5% are held by institutions.
Frequently Asked Questions About BioCryst Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.